Last €65.13 EUR
Change Today -1.08 / -1.63%
Volume 0.0
NOTA On Other Exchanges
Symbol
Exchange
Xetra
New York
Frankfurt
SIX Swiss Ex
As of 3:00 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-adr (NOTA) Snapshot

Open
€65.14
Previous Close
€66.21
Day High
€66.03
Day Low
€65.13
52 Week High
07/7/14 - €67.67
52 Week Low
07/31/13 - €53.14
Market Cap
176.3B
Average Volume 10 Days
160.3
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
02/27/14
P/E TM
--
Dividend
€2.70
Dividend Yield
3.09%
Current Stock Chart for NOVARTIS AG-ADR (NOTA)

novartis ag-adr (NOTA) Details

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company’s Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company’s Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

135,000 Employees
Last Reported Date: 07/17/14
Founded in 1895

novartis ag-adr (NOTA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.3.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.747.1K
President of Institutes for Biomedical Resear...
Total Annual Compensation: $1.9M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $2.0M
Division Head of Animal Health and Member of ...
Total Annual Compensation: SFr.1.4M
Compensation as of Fiscal Year 2013.

novartis ag-adr (NOTA) Key Developments

Novartis Announces Earnings Results for the Second Quarter and First Half Ended June 2014; Provides Earnings Guidance for the Full Year of 2014

Novartis announced earnings results for the second quarter and first half ended June 2014. For the quarter, the company reported net sales of $14,637 million, operating income of $3,095 million, net income of $2,585 million or $1.05 per share, core operating income of $3,797 million, core net income of $3,283 million or $1.34 per share, compared to the net sales of $14,488 million, operating income of $2,970 million, net income of $2,548 million or $1.03 per share, core operating income of $3,692 million, core net income of $3,188 million or $1.29 per share for the same quarter a year ago. Free cash flow was $2,413 million compared to $1,785 million a year ago. For the first half, the company reported net sales of $28,659 million, operating income of $6,584 million, net income of $5,553 million or $2.26 per share, core operating income of $7,454 million, core net income of $6,495 million or $2.64 per share, compared to the net sales of $28,233 million, operating income of $5,866 million, net income of $4,970 million or $2.01 per share, core operating income of $7,343 million, core net income of $6,397 million or $2.59 per share for the same period a year ago. As  of the end of June 2014, the net  debt stood at $13.1 billion compared to $8.8 billion at December 31, 2013. The increase of $4.3 billion was driven by the dividend payment of $6.8 billion, share repurchases of $4.3 billion and  other  net  cash  outflow  items  of  $0.1 billion.  This was partially compensated  by the free cash flow of $3.2 billion compared to $3,083 million a year ago, the proceeds from options exercised of $2.4 billion and $1.3 billion of divestment proceeds. The company announced that it was keeping its full-year forecast of a growth in turnover of low to mid-single digits. Group core operating income is expected to grow ahead of sales (cc) in 2014, and now refined to mid to high-single digit (cc).

Google Announces Partnership with Novartis to Develop Innovative Contact Lens

Google has announced a partnership with Novartis to develop a smart contact lens that can monitor the glucose levels in the eye. Google first unveiled the concept in January, which works using tiny sensors and microchips fitted into contact lenses that can then measure and read the amount of glucose in tears, before sending the information to a mobile device so diabetics can manage their condition.

Novartis Launches New Formulation Coartem Tablet in Kenya

Novartis has launched a new formulation of the anti-malaria drug Coartem in Kenya. The Star, the new formation, known as Coartem 80/480, requires patients to consume two tablets for three days, compared with eight pills a day over three days for standard Coartem formulations. The drug may be made available nationwide in Kenya once the government has moved to procure stock. Coartem 80/480 has been approved in Angola, Ghana, Nigeria, and Uganda.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOTA:GR €65.13 EUR -1.08

NOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $89.84 USD -0.70
Merck & Co Inc $58.15 USD -0.06
Roche Holding AG SFr.266.30 CHF -0.70
Sanofi €76.64 EUR +0.66
Procter & Gamble Co/The $79.56 USD -0.70
View Industry Companies
 

Industry Analysis

NOTA

Industry Average

Valuation NOTA Industry Range
Price/Earnings 23.7x
Price/Sales 3.6x
Price/Book 3.0x
Price/Cash Flow 24.5x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.